- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Ryan Huey: Expansion of Patient Support, Care Key to Improve Value-Based Oncology
There are various areas across different patient care and support perspectives that offer opportunities to improve value-based care in oncology, said Ryan Huey, MD, gastrointestinal medical oncologist at MD Anderson Cancer Center in Houston, Texas.
Patient services across various perspectives such as direct patient care and patient support are areas that health systems can expand upon to improve value-based oncology care, said Ryan Huey, MD gastrointestinal medical oncologist at MD Anderson Cancer Center in Houston, Texas.
Transcript
What actions can health systems take to improve value-based oncology care within their organizations?
I think from a direct patient care perspective, there's a role to think about the expanded use of telemedicine and also potentially, chemotherapy even at home, or certainly closer to where a patient lives as opposed to in a traditional infusion suite or a hospital. From a support services perspective, there's a role to expand a lot of services. Some of these were described in the Oncology Care Model such as social work or nutritional support or navigation, physical therapy, palliative care; these are things that are not traditionally reimbursed in a fee-for-service environment, however, can lead to improved outcomes for patients or reduced costs throughout the patient journey. So, this is an excellent way to also think about expanding the use of value-based care in the oncology space
AI's Role in Oncology: Supporting, Not Replacing, Health Care Providers
January 9th 2025In this second half of our interview with Vanderbilt University Medical Center’s Travis Osterman, DO, MS, FAMIA, FASCO, he discusses opportunities for advancing the smart use of artificial intelligence (AI) in cancer care.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Leveraging AI and Community Health Workers to Boost Trial Access
January 4th 2025In this second part of our interview with Kasey Bond, MPH, NYU Langone Health, we discuss the contributions of community health workers to increasing clinical trial access and how technology—artificial intelligence (AI), in particular—can help to facilitate the process.
Read More
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurativa (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
